Posts by John

The FDA has approved a breakthrough multiple myeloma therapy. Discover how this new targeted treatment could improve survival rates for refractory patients.

EU regulators are investigating serious clinical trial breaches for Tavneos, raising questions about the drug's future market status in ANCA-associated vasculitis.

Discover how the WHO is empowering African nations to strengthen medical device oversight through new standardized self-benchmarking regulatory tools.

The FDA has approved Zenbexii, the first CELMoD therapy for relapsed or refractory multiple myeloma, offering a new treatment pathway for patients.

The FDA has granted Fast Track designation to Spevatamig for treating advanced biliary tract carcinoma, offering new hope for targeted cancer therapy.

New research reveals sepsis survivors experience inconsistent immune responses to vaccines. Discover the implications for recovery and clinical care.

New research finds that astaxanthin supplementation significantly improves cognitive function and mental focus in active women. Read the full analysis here.

New clinical research confirms EpiCor postbiotic intake leads to rapid immune biomarker changes, offering a science-backed boost to innate immunity.

Fate Therapeutics moves into a registrational trial for its iPSC-derived cell therapies, a major step toward scaling off-the-shelf cancer treatment.

Panthera launches a new clinical research site at Keele University to accelerate drug development and expand patient access to cutting-edge trials.